Company
Amplia Therapeutics Limited
Headquarters: Melbourne, VIC, Australia
CEO: Dr. John Lambert B.Sc., BSc (Hons), C.Chem., MRACI, Ph.D.
Market Cap
A$15.7 Million
AUD as of Jan. 1, 2024
US$10.7 Million
Amplia Therapeutics Limited Categories
Australia Healthcare BiotechnologyAustralia Healthcare Australia Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Amplia Therapeutics Limited, a pharmaceutical company, engages in the development of focal adhesion kinase (FAK) inhibitors in Australia. The company is developing inhibiting drug candidates, including AMP886 and AMP945 for oncology and chronic fibrosis indications. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Amplia Therapeutics Limited has the following listings and related stock indices.
Stock: ASX: ATX wb_incandescent